All In Biotech

Free tool

FAERS Monitor: Nypozi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761126 or its brand name (Nypozi, Filgrastim-Txid). Reports on generic versions are filed under their own applications.

Reports

55

Serious

55

100% of reports

Hospitalization

8

Death reported

39

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • adverse event27
  • death20
  • febrile neutropenia8
  • off label use1

Reports by year received

View as table
YearReports
20245
202510
202640

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,104 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
adverse eventSignal27112.185.62,874
febrile neutropeniaSignal846.124.3310
deathSignal208.96.3138
off label use10.40.10

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.